First-in-class glucokinase activator (GKA) HuaTangNing (dorzagliatin) was approved in China in September 2022. Since the launch of commercial sales at…
Browsing: Hua Medicine
Hua Medicine (Stock Code: 2552.HK), today announced that the New Drug Application (NDA) for dorzagliatin for the treatment of Type…
Hua Medicine (the “Company”, Stock Code: 2552.HK), today announces the audited annual results of the Company and its subsidiaries for…
Hua Medicine (the “Company”, Stock Code: 2552.HK) announces that, after review and on-site verification under the Marketing Authorization Holder (“MAH”)…
Hua Medicine today announced the positive 24-week top-line results from HMM0302, a Phase III registration trial in China of its…
Hua Medicine (the “Company”, Stock Code: 2552.HK), a leading innovative drug development company focused on developing…
Hua Medicine (the “Company”, Stock Code: 2552. HK) today announces the positive results of the clinical study HMM0112. HMM0112 is…
Pivotal Phase III Trial Achieved Clinical Efficacy Endpoint at 24 Weeks Dorzagliatin-Driven Portfolio Expands Hua Medicine (the “Company”, Stock Code…
Hua Medicine, a leading clinical stage biotechnology company based in Shanghai, is pleased to announce that Dr. Fuxing Tang has…